• / Free eNewsletters & Magazine
  • / My Account
Home>US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

3party Content

Wed, 18 Oct 2017

US FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in Metastatic Breast Cancer and Grants Priority Review

©2017 Morningstar Advisor. All right reserved.